Feature | April 27, 2015

New Concept of Heart Disease Posits Vitamin C Deficiency as Culprit

Study of transgenic mouse model shows chronic vitamin C deficiency leads to structural weakness of blood vessel walls, causing atherosclerotic development

April 27, 2015 — Scientific confirmation has just been published in the American Journal of Cardiovascular Disease that atherosclerosis, the underlying process of heart attacks and strokes, is generally not caused by high cholesterol blood levels. It is rather the result of a structural weakness of the blood vessel walls caused by chronic deficiency of ascorbate (vitamin C).

Heart attacks, strokes and other forms of cardiovascular disease are the single largest disease on our planet with more than 17 million deaths each year. The continuation of this disease in epidemic proportions proves that its true nature has not yet been sufficiently understood. Moreover, the current hypothesis that high cholesterol levels in blood triggers cardiovascular disease cannot answer the most basic question of cardiology: Cholesterol has the same concentration in both arteries and veins. So why do atherosclerotic plaques occur only in arteries – but not in veins? Moreover, why do they develop almost always in the few inches of coronary arteries – but rarely in other organs? Or why is atherosclerosis, a hallmark of the human race, basically unknown in animal species? 

Researchers from the Dr. Rath Research Institute in California developed a unique animal model. It is a transgenic mouse that resembles human metabolism in its key aspects, the inability to produce vitamin C and, at the same time, the synthesis of human Lipoprotein(a) – a variant of low-density-lipoprotein (LDL).  Using this animal model they demonstrated that atherosclerosis, generally, starts with a dietary depletion of vitamin C and the ensuing structural weakness of the artery walls. This metabolic condition results in an increase in serum Lipoprotein(a) levels and its accumulation in the vascular wall that parallels atherosclerotic lesion development.

This study confirms the scientific concept published in 1990 in the 'Proceedings of the National Academy of Sciences, USA' by Matthias Rath, M.D., together with two-time Nobel Prize winner Linus Pauling, M.D. They proposed that Lipoprotein(a) is a repair molecule that functions as a surrogate for vitamin C in the impaired vascular wall. 

The most fascinating aspect of this animal model is the fact that it reproduces a genetic switch, the disappearance of vitamin C to the appearance of Lipoprotein(a), from about 40 million years ago. It proves the concept that a distinct event during the evolution of man can explain the susceptibility of modern man to cardiovascular disease.

For more information: www.ajcd.us

Related Content

American College of Cardiology Expands Patient Navigator Program
News | Cath Lab | March 21, 2018
March 21, 2018 — Hundreds of hospitals across the United States will have access to tools and resources to help impro
Videos | Cath Lab | March 15, 2018
A discussion with Hitinder Gurm, M.D., MBBS, FACC, professor, internal medicine, and associate chief clinical officer
News | Cath Lab | February 27, 2018
The American College of Cardiology (ACC) and the Saudi Arabian Cardiac Interventional Society have partnered to...
News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Overlay Init